Evotec SE stock (DE0005664809): Goldman Sachs voting-rights disclosure keeps biotech share in focus after Nasdaq exit

Evotec SE stays on the radar of international investors as Goldman Sachs reports a voting-rights position in the German biotech, while trading liquidity concentrates on the Frankfurt listing after the 2024 Nasdaq delisting.

Evotec SE remains in the spotlight for European and US-oriented biotech investors after a recent voting-rights notification involving Goldman Sachs was published, highlighting institutional interest in the Hamburg-based drug discovery specialist and its primary listing on Xetra in Frankfurt, according to EQS-News as of 05/15/2025.

In parallel, the stock continues to trade solely in Germany after the delisting of Evotec’s American Depositary Shares from Nasdaq in 2024, a move that shifted international trading activity back to Frankfurt and keeps the upcoming strategy and earnings updates in focus for many cross-border investors, as outlined by Ad-hoc-news as of 03/24/2025.

As of: 22.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Evotec SE
• Sector/industry: Biotechnology, drug discovery and development services
• Headquarters/country: Hamburg, Germany
• Core markets: Europe and North America with a strong US customer base
• Key revenue drivers: Research alliances, fee-for-service contracts, milestones and royalties from partnered drug candidates
• Home exchange/listing venue: Xetra (ticker: EVT)
• Trading currency: Euro (EUR)

Evotec SE: core business model

Evotec positions itself as a global partner for pharmaceutical and biotechnology companies across the drug discovery and early development value chain. The group offers integrated research services that span from target identification and validation through hit finding, lead optimization and preclinical development stages, according to MarketScreener as of 05/10/2025. This business-to-business model aims to generate recurring service revenues alongside longer-term upside from milestone and royalty agreements.

Rather than developing an extensive fully owned pipeline, Evotec typically works under partnership structures in which large pharma or emerging biotech clients bear a significant part of the late-stage clinical and commercialization risk. Evotec contributes its discovery platforms, scientific know-how and project execution capabilities, while partners fund, steer and, if successful, commercialize resulting medicines. In return, Evotec can earn research fees, success-based milestones and potential royalties on net sales, as outlined by Ad-hoc-news as of 03/24/2025.

The company operates multiple technology platforms across key therapeutic areas such as neurology, metabolic diseases, oncology and anti-infectives. These platforms include high-throughput screening, structural biology, medicinal chemistry and in-vitro as well as in-vivo pharmacology capabilities. By clustering capabilities on shared campuses, Evotec aims to address efficiency and speed needs of clients that want to accelerate their early-stage pipelines without building all capabilities in-house, a model that can be particularly attractive for US biotech firms managing capital-intensive R&D.

Main revenue and product drivers for Evotec SE

Evotec’s revenue base is primarily driven by contract research and development services for pharmaceutical and biotechnology partners. Under these collaborations, the company invoices discovery and early development work on a fee-for-service or full-time-equivalent basis, which provides relatively visible short-term revenue streams. According to descriptions on MarketScreener as of 05/10/2025, this service business represents the backbone of Evotec’s operating model.

In addition to research services, Evotec’s alliances often include success-based components such as development milestones triggered when partnered drug candidates reach specific clinical or regulatory stages. While such payments tend to be less predictable and can fluctuate from year to year, they provide leverage to positive R&D outcomes. Over the long term, Evotec also targets recurring royalties from commercialized products that originated from its platforms, creating a potential second layer of revenue if multiple partnered assets progress successfully.

On the product side, Evotec is involved in a broad partnered pipeline, from discovery to clinical stages, rather than concentrating on a few wholly owned late-stage drugs. For investors, this diversified approach can spread scientific and development risk across many programs and therapeutic areas, but it also means that the company’s economics per asset may be lower than a traditional biotech that fully owns its flagship candidates. The balance between scalable service income and shared upside from co-discovery deals is therefore a central topic in the equity story.

Goldman Sachs voting-rights disclosure: why it matters

The recent voting-rights announcement involving Goldman Sachs attracted attention because it provides a glimpse into institutional ownership dynamics around Evotec following the US delisting. In Germany, significant shareholdings and changes above certain thresholds must be reported and published under the Securities Trading Act, which is why the disclosure appeared in an official regulatory filing, according to Deutsche Börse live as of 05/15/2025.

While such notifications do not automatically indicate a specific investment thesis or long-term intention, they highlight that a global financial institution like Goldman Sachs is active in the shareholder structure. For some market participants, this can be a signal of ongoing institutional engagement with the stock, which may be particularly relevant after the American Depositary Shares were removed from Nasdaq and some US-focused funds adjusted their mandates. At the same time, regulatory filings are neutral in nature and do not provide qualitative commentary on the company’s fundamentals.

For Evotec, the voting-rights news sits alongside a broader period of transition in its capital-market presence. The firm continues to emphasize its core Xetra listing and German regulatory framework while still attempting to maintain visibility with international investors. Observers therefore watch ownership disclosures, liquidity indicators and research coverage to gauge how the shareholder base is evolving in the post-Nasdaq environment.

Industry trends and competitive position

Evotec operates in the global market for outsourced drug discovery and early development services, a segment that has grown as pharmaceutical companies seek to optimize R&D productivity by collaborating with specialized external partners. Rising complexity in biology, increasing data volumes and a push for faster time-to-clinic have made platform-based discovery providers more critical to large and mid-sized pharma pipelines, according to sector commentary referenced by MarketScreener as of 05/10/2025.

Within this landscape, Evotec competes with other contract research organizations and discovery specialists that offer overlapping capabilities, but the company positions itself as a partner with integrated platforms rather than a pure fee-based service provider. This includes combining high-throughput experimental platforms with computational approaches and disease-area expertise, which can help differentiate the offering. Competition is nevertheless intense, as global CROs, niche biotech service firms and in-house pharma labs all vie for discovery budgets.

Macro trends in biotech funding and pharma R&D budgets also influence Evotec’s environment. Periods of robust capital markets tend to support early-stage biotech formation and project initiation, while more challenging funding conditions can lead to delays or cancellations of discovery projects. For a partner-driven model like Evotec’s, diversification across multiple clients and indications is intended to mitigate cyclical swings, but the company still remains exposed to the broader health of the life-science innovation ecosystem.

Why Evotec SE matters for US investors

Even though Evotec’s American Depositary Shares were delisted from Nasdaq in 2024, the company still maintains a significant commercial footprint in North America and works with US-based pharmaceutical and biotechnology customers. That makes the stock relevant for US investors who look beyond domestic listings and access European names via international trading platforms and custody solutions, as contextualized by Ad-hoc-news as of 03/24/2025.

For US-based portfolio managers with a global healthcare mandate, Evotec offers exposure to early-stage drug discovery economics that are structurally different from typical US biotech models focused on fully owned pipelines. Instead, the German group participates in a broad range of partnered programs, combining recurring service revenues with option-like upside to clinical success. This can be used as a diversification tool in portfolios that already contain US-focused biotech innovators and large pharmaceuticals.

Additionally, Evotec provides a window into European regulatory frameworks, disclosure practices and capital-market structures that differ from those in the United States. Voting-rights announcements such as the recent Goldman Sachs disclosure exemplify the transparency rules under German securities law, which some US investors consider when assessing governance and shareholder dynamics in foreign holdings. Accessing such information can help them contextualize the risk-return profile of a non-US biotech services provider.

Conclusion

Evotec SE stands out as a European biotech services provider that combines contract research income with upside from partnered drug candidates, while trading exclusively in Frankfurt following the 2024 Nasdaq delisting. The recent Goldman Sachs voting-rights disclosure underscores that international institutions remain active in the shareholder base, even as liquidity has shifted away from the US market. For globally oriented investors, Evotec offers differentiated exposure to the drug discovery outsourcing trend, but the company’s performance will continue to depend on partner demand, execution on its platforms and the progression of its broad, largely partnered pipeline.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.